Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron vs Metoclopramide for GERD in Infants
NCT06898268Completed
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ondansetron in gastroesophageal reflux disease (GERD) (2 arms). Primary endpoints: Response to treatment at 1 week and Treatment-emerged adverse events at 1 week. Started Jul 2024; status: completed.
02
Drugs
ondansetron
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06898268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06898268.